MedTrace Logo

Boron Phenylalanine With or Without Mannitol in Treating Patients With Glioblastoma Multiforme

NCT01233492 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2013-10-08

No results posted yet for this study

Summary

RATIONALE: Giving boron phenylalanine in different ways and measuring it in tissue in patients with glioblastoma multiforme may help in planning better radiation therapy, such as boron neutron capture therapy, for patients in the future.

PURPOSE: This phase I trial is studying the side effects, best dose boron phenylalanine, and best way of giving it with or without mannitol in treating patients with glioblastoma multiforme.

Conditions

Interventions

DRUG

boron phenylalanine

DRUG

mannitol

OTHER

biologic sample preservation procedure

RADIATION

radiation therapy treatment planning/simulation

Sponsors & Collaborators

Principal Investigators

  • Garth Cruickshank · University Hospital Birmingham

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01233492 on ClinicalTrials.gov